Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Drugmakers say UK could lose out on EU anti-counterfeit drugs push

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2019 | 07:18pm EST
FILE PHOTO: Used blister packets that contained medicines, tablets and pills are seen, in this picture illustration

(Reuters) - Drugmakers warned on Friday that if Britain leaves the European Union without a deal next month Britons could miss out on an EU-wide system to fight counterfeit drugs that will go live on Saturday after years of British involvement in building it.

Drugmakers, wholesalers and pharmacies across Europe have worked for more than four years on a system based on a shared database and tamper-proof packages with barcodes that will go live on Saturday, to fulfil the European Union's Falsified Medicines Directive (FMD).

"It would be an absolute travesty if NHS patients aren't part of a system specifically designed to protect them. But that's exactly what could happen in a 'no deal' Brexit," Rick Greville, Director of Supply Chain at the Association of the British Pharmaceutical Industry (ABPI), said in a statement by the lobby group.

"It is just another reason why we urgently need a Brexit deal," he added.

The British government, which says that about three-quarters of medicines used by the state-run National Health Service (NHS) come via the EU, has outlined plans to ensure Britain has an extra six weeks of drug supplies in the event of a no-deal Brexit.

The global counterfeit drug market is worth around $200 billion (£154 billion) annually, the World Health Organisation says, with often devastating consequences for unsuspecting patients, many of whom live in the developing world.

The problem was highlighted in October by coordinated police raids in 116 countries that netted 500 tonnes of illicit pharmaceuticals available online, including fake cancer medications and pain pills.

The European Medicines Verification System (EMVS) will allow dispensing pharmacists to scan drug packages and link up to a database to give patients assurance on the product's authenticity.

The European Union said on Thursday it would work with Theresa May on whether a way could be found to avoid the disruption of a no-deal Brexit on March 29, after the British prime minister demanded changes to the divorce deal to get it through parliament.

The highly regulated drugs sector is seen as one of the most vulnerable to a no-deal outcome due to its pan-European supply chains and need for regulatory oversight.

(Reporting by Ludwig Burger; Editing by Frances Kerry)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 1.50% 6241 Delayed Quote.6.27%
GLAXOSMITHKLINE 0.96% 1581 Delayed Quote.5.02%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
02/14ASTRAZENECA : Up Over 9% After 4Q Revenue, Core EPS Beats -- Data Talk
DJ
02/14LONDON STOCK EXCHANGE : FTSE 100 squeezes out gains; ConvaTec drags midcaps
RE
02/14European shares give up three-month highs after shock U.S. data
RE
02/14LONDON MARKETS: London Stocks Cling To Gains; AstraZeneca Surges On Results
DJ
02/14ASTRAZENECA : Turns a Corner After a Decade of Struggles -- 3rd Update
DJ
02/14EUROPE MARKETS: Trade Optimism Helps European Stocks Shrug Off Growth Fears
DJ
02/14GLOBAL MARKETS LIVE : Google, Airbus, Volkswagen, Cisco…
02/14ASTRAZENECA : New cancer drugs, China give AstraZeneca welcome sales boost
RE
02/14ASTRAZENECA : Set for Growth in 2019 -- Earnings Review
DJ
02/14ASTRAZENECA : 4Q Earnings Snapshot
AQ
More news
Financials ($)
Sales 2019 23 428 M
EBIT 2019 6 122 M
Net income 2019 2 806 M
Debt 2019 14 781 M
Yield 2019 3,40%
P/E ratio 2019 36,45
P/E ratio 2020 25,54
EV / Sales 2019 4,96x
EV / Sales 2020 4,51x
Capitalization 101 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 82,1 $
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA6.27%101 309
JOHNSON & JOHNSON4.08%365 768
PFIZER-3.85%245 920
ROCHE HOLDING LTD.11.98%233 242
NOVARTIS7.19%228 685
MERCK AND COMPANY4.45%207 536